# Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4

> **NCT04559204** · PHASE4 · COMPLETED · sponsor: **China National Biotec Group Company Limited** · enrollment: 1224 (actual)

## Conditions studied

- Influenza, Human
- Pneumonia, Pneumococcal

## Interventions

- **BIOLOGICAL:** IIV4 and PPV23
- **BIOLOGICAL:** IIV4
- **BIOLOGICAL:** PPV23

## Key facts

- **NCT ID:** NCT04559204
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-11
- **Primary completion:** 2020-11-26
- **Final completion:** 2021-10-09
- **Target enrollment:** 1224 (ACTUAL)
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04559204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04559204, "Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04559204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*